TCGA-COADREAD Samples Report
2019_12_16 Data Snapshot
- Overview
+ Introduction
- Summary

There were 0 redactions, 0 replicate aliquots, 0 blacklisted aliquots, and 0 FFPE aliquots. The table below represents the sample counts for those samples that were ingested into firehose after filtering out redactions, replicates, and blacklisted data, and segregating FFPEs.

Table 1.  This table provides a breakdown of sample counts on a per sample type and, if applicable, per subtype basis. Each count is a link to a table containing a list of the samples that comprise that count and details pertaining to each individual sample (e.g. platform, sequencing center, etc.). Please note, there are usually multiple protocols per data type, so there are typically many more rows than the count implies.

Sample.Type BCR Clinical CN mRNA miR MAF Methylation
FFPE 13 13 12 13 7 12 12
NB 509 505 509 0 0 0 0
TR 2 2 2 2 2 2 1
TP 633 629 617 622 605 589 623
TM 1 1 1 1 1 1 1
NT 110 110 107 51 11 0 87
Totals 633 629 617 622 605 589 623

The sample type short letter codes in the table above are defined in the following list.

  • TP: Primary Tumor

  • TR: Recurrent Tumor

  • TB: Primary Blood Derived Cancer - Peripheral Blood

  • TRBM: Recurrent Blood Derived Cancer - Bone Marrow

  • TAP: Additional - New Primary

  • TM: Metastatic

  • TAM: Additional Metastatic

  • THOC: Human Tumor Original Cells

  • TBM: Primary Blood Derived Cancer - Bone Marrow

  • NB: Blood Derived Normal

  • NT: Solid Tissue Normal

  • NBC: Buccal Cell Normal

  • NEBV: EBV Immortalized Normal

  • NBM: Bone Marrow Normal

  • CELLC: Control Analyte

  • TRB: Recurrent Blood Derived Cancer - Peripheral Blood

  • CELL: Cell Lines

  • XP: Primary Xenograft Tissue

  • XCL: Cell Line Derived Xenograft Tissue

Figure 1.  Get High-res Image This figure depicts the distribution of available data on a per participant basis.

- Results
+ Methods & Data